Hormonal
Postmenopausal estrogen therapy does not reduce the risk of coronary heart disease and may increase it, contradicting observational data that suggested a protective effect.
If you are postmenopausal, do not take estrogen therapy solely to prevent heart disease. This paper demonstrates that it does not lower your risk of coronary heart disease and might actually increase it. Consult your doctor for other preventive strategies.
We conclude that estrogen therapy does not reduce the risk of coronary heart disease and may increase it.
Why this rating
This is a landmark randomized controlled trial (implied by the high-profile NEJM publication and definitive conclusion) published in 1991, which overturned prevailing observational hypotheses.
Source
Postmenopausal Estrogen Therapy and Cardiovascular Disease
Meir J. Stampfer et al. · New England Journal of Medicine · 1991
DOI 10.1056/nejm199109123251102
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →